ReviewCureus2025
Efficacy and Safety of Tislelizumab as an Immune Checkpoint Inhibitor for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a leading global cause of cancer-related mortality, necessitating effective systemic therapies. Tislelizumab, a novel anti-PD-1 monoclonal antibody, has shown promise in recent trials. However, a pooled assessment of its clinical efficacy and safety in HCC treatment has been lacking. To systematically evaluate and quantify the efficacy and safety of tislelizumab in HCC, focusing on key outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (TRAEs), a systematic search of PubMed, Scopus, Cochrane Library, ScienceDirect, the American Society of Clinical Oncology (ASCO), and the European Society of Medical Oncology (ESMO) databases was conducted for clinical trials from January 2010 to October 2024. Seven studies involving 1,178 patients were included in the analysis. Statistical analyses were performed using the Comprehensive Meta-Analysis software (version 3.7). Fixed-effect and random-effects models were used based on heterogeneity (I² statistic), and publication bias was assessed using Egger's and Begg's tests, alongside Duval and Tweedie's trim-and-fill method. The pooled ORR was estimated at 22.3% (logit = -1.242; SE = 0.0897), but after correcting for publication bias (Egger's p = 0.027), the adjusted ORR decreased to 17.2%. The pooled OS was 13.66 months (95% CI: 11.97-15.35) with no heterogeneity (I² = 0%), affirming the robustness of the survival benefit. PFS was 4.58 months under a fixed-effect model but increased to 5.86 months with the random-effects model due to high heterogeneity (I² = 93.15%). The incidence of Grade ≥ 3 TRAEs was 28.9% (logit = -0.448), indicating a manageable safety profile, with no significant publication bias (Egger's p = 0.251). Tislelizumab demonstrates favorable clinical activity in HCC, offering meaningful improvements in survival and disease control with acceptable toxicity. While ORR results were influenced by potential publication bias, survival and safety outcomes were consistent and reliable. These findings support tislelizumab as a viable immunotherapeutic option for advanced HCC, warranting further exploration in larger, randomized trials and combination therapy regimens to optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.